

## RESEARCH

### BOB Economics Research | Currency Outlook

Surge in oil prices remains key risk to INR

### BOB Economics Research | Monsoon Impact

Is normal monsoon a good indicator for agriculture?

### L&T Infotech | Target: Rs 8,140 | +49% | BUY

Soft growth; maintain BUY on strong TCV

## SUMMARY

### India Economics: Currency Outlook

Global currencies closed lower against the dollar. Fed's aggressive policy tightening, rising treasury yields as well as improved US macro data supported gains in DXY. On the other hand, JPY and EUR fell amidst widening policy divergence with the Fed. INR has depreciated by 0.7% in Apr'22, led by a surge in oil prices in the last few days. FPIs outflows have moderated but are likely to remain muted as Fed starts its policy tightening. The rupee is likely to remain in the range of Rs 76-77/\$ till the end of the month. A further spike in oil prices may put pressure on INR.

[Click here for the full report.](#)

### India Economics: Monsoon Impact

Every year, before the beginning of the monsoon season, different agencies predict if the rainfall will be normal or not. How have these conditions fared in the past? Does normal monsoon translate in to good crop production? Is this the sole criteria or are there other factors at play. While there is no denying that monsoon is critical condition for higher crop production, as 60% of the cultivable land in India relies on South West Monsoon, uniform distribution of rainfall along with other climatic conditions drive the production higher/lower. This note attempts to shed light on the same and see how other host of factors are responsible for agriculture growth.

[Click here for the full report.](#)

### Daily macro indicators

Indicator	14-Apr	18-Apr	Chg (%)
US 10Y yield (%)	2.83	2.85	3bps
India 10Y yield (%)	7.22	7.15	(6bps)
USD/INR	76.18	76.26	(0.1)
Brent Crude (US\$/bbl)	111.7	113.2	1.3
Dow	34,451	34,412	(0.1)
Hang Seng	21,374	21,518	0.7
Sensex	58,339	57,167	(2.0)
India FII (US\$ mn)	12-Apr	13-Apr	Chg (\$ mn)
FII-D	(7.2)	(69.3)	(62.2)
FII-E	(349.4)	(126.0)	223.4

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



**L&T Infotech**

- Q4 revenue growth of 3.6% QoQ CC below our estimate of 5%; however, net new TCV robust at US\$ 80mn, up 21% YoY
- EBIT margin largely in line at 17.3%, down 60bps QoQ due to rising employee cost
- We prune FY23/FY24 EPS by 4%/2% and roll over to a new TP of Rs 8,140 (vs. Rs 8,490). Retain BUY on strong guidance and robust TCV

[Click here](#) for the full report.

## CURRENCY OUTLOOK

18 April 2022

### Surge in oil prices remains key risk to INR

Global currencies closed lower against the dollar. Fed's aggressive policy tightening, rising treasury yields as well as improved US macro data supported gains in DXY. On the other hand, JPY and EUR fell amidst widening policy divergence with the Fed. INR has depreciated by 0.7% in Apr'22, led by a surge in oil prices in the last few days. FPIs outflows have moderated but are likely to remain muted as Fed starts its policy tightening. The rupee is likely to remain in the range of Rs 76-77/\$ till the end of the month. A further spike in oil prices may put pressure on INR.

**Aditi Gupta**  
Economist

#### How have currencies fared?

Most global currencies have depreciated against the dollar in Apr'22 (as of 18 Apr 2022). DXY has strengthened, supported by better macro prints, hike in US treasury yields and hawkish commentary by Fed. In Apr'22 so far, DXY has risen by 2.4% to a more than 2-year high. On the other hand, Japanese yen (JPY) depreciated further by 3.9% to a 20-year low, amidst rising yield differentials from the US as well as concerns over rising oil prices and external stability. EUR has also depreciated by 2.4% in the period. This is because of rising policy divergence between ECB and US Fed. Furthermore, risks of stagflation as well as uncertainty over French Presidential elections continue to weigh on the EUR. New Zealand dollar depreciated by 3.1% even as Reserve Bank of New Zealand raised policy rates by 50bps (highest rate hike in 22-years) amidst surging inflation.

On the other hand, currencies such as Brazilian real, Turkish lira and Indonesian rupiah have appreciated against the dollar.

#### INR performance:

INR has depreciated by 0.7% in Apr'22 so far. The movement in INR can be traced back to the movement in oil prices. INR depreciated by only 0.2% between 1-11 Apr 2022, when oil prices averaged US\$ 103/bbl. In the same period, FII outflows were US\$ 5.5bn. Subsequently, oil prices have averaged US\$ 109.3/bbl, leading to a 0.4% depreciation in INR. With oil prices on an uptrend again, INR is likely to come under renewed pressure.

#### Currency volatility:

Apart from daily changes in currencies, volatility is also a major factor for the markets. Here, we have looked at the volatility in two periods; 16-31 Mar 2022 and 1-18 Apr 2022. For almost all currencies, volatility has declined in the latter period.



**MONSOON IMPACT**

19 April 2022

**Jahnavi**  
Economist**Is normal monsoon a good indicator for agriculture?**

Every year, before the beginning of the monsoon season, different agencies predict if the rainfall will be normal or not. How have these conditions fared in the past?

Does normal monsoon translate in to good crop production? Is this the sole criteria or are there other factors at play. While there is no denying that monsoon is critical condition for higher crop production, as 60% of the cultivable land in India relies on South West Monsoon, uniform distribution of rainfall along with other climatic conditions drive the production higher/lower. This note attempts to shed light on the same and see how other host of factors are responsible for agriculture growth.

**1. How do we measure normal monsoon:** A normal Monsoon is defined as rainfall between 96%-104% of LPA (Long period average). LPA of June-Sep'22 period is basically average rainfall received in the past 50-years for the period of 1971-2020 (revised this year from 1961-2010) and is estimated at 88cm for the current year. While normal rainfall is 96-104% of the LPA, less than 90% of LPA is termed as deficit rainfall and more than 110% in excess rainfall. For the LPA range between 90-96% of the LPA, is referred to as below normal and between 104-110% of LPA is categorized as above normal rainfall. South-West monsoon lasts for the period of June to September in every year.

Private organizations such as Skymet and government organization namely IMD predicts monsoon each year. Both Skymet and IMD forecast carry the model error of (+ -) 5% and have estimated normal monsoon for the current year. It is interesting to notice, that in the past there has been much higher deviation in actual rainfall compared with the first IMD forecast. Specially, a much higher deviation level was seen for the year 2019 and 2020.

As per IMD, La-Nina conditions are prevailing over the equatorial region and is expected to continue during the monsoon season for this year. La-Nina is the cool phase of the recurring climate pattern across the pacific. EL-Nino is the warm phase. The southern oscillation index (SOI) signals the development, along with intensity of both these phases. Continuous negative values of SOI lower than (-) 7 implies EL-Nino, while continuous positive value of SOI greater than 7 signal the likelihood of La-Nina. El Nino- impacts the monsoon negatively and La-Nina has a positive impact on the monsoon.

**2. Is good monsoon a necessary or sufficient condition for good crop:** It is believed that monsoon has a direct bearing on India's agriculture growth. To understand the same, agriculture and allied sectors had moderated marginally by 20bps in FY18 as against FY17 when the monsoon was below normal. Following this, agriculture growth dwindled to as low as 2.2% in FY19 from 6.6% in FY18 which was the period of below normal monsoon. Foodgrains production was also lower.



**BUY**  
 TP: Rs 8,140 | ▲ 49%

**L&T INFOTECH**

Technology & Internet

20 April 2022

**Soft growth; maintain BUY on strong TCV**

- Q4 revenue growth of 3.6% QoQ CC below our estimate of 5%; however, net new TCV robust at US\$ 80mn, up 21% YoY
- EBIT margin largely in line at 17.3%, down 60bps QoQ due to rising employee cost
- We prune FY23/FY24 EPS by 4%/2% and roll over to a new TP of Rs 8,140 (vs. Rs 8,490). Retain BUY on strong guidance and robust TCV

**Seema Nayak**

researchreport@bobcaps.in

**Revenue miss:** LTI's Q4FY22 revenue grew 3.6% QoQ CC vs. our estimate of 5%, after two consecutive quarters of 9%+ sequential growth. BFS/manufacturing saw muted growth of 2.8%/1.9% QoQ USD whereas the CPG, retail and pharma vertical performed well (+6.2%), followed by insurance (+3.9%) which recovered from a slump in Q3. Top-10 client growth was muted at 3.1% QoQ. However, on a full-year basis, LTI posted its highest-ever dollar revenue growth of 25.9% in FY22.

**Margin in line:** Q4 EBIT margin stood at 17.3% (17.9% est.), down 60bps QoQ due to increased employee cost. SG&A cost dipped 1.7% QoQ. Attrition surged to an alarming level of 24%, up 150bps QoQ and doubling YoY. LTI added 2,400 employees QoQ in Q4 and plans to roll out salary hikes from Apr'22. Amid rising employee cost due to the elevated attrition, management used the offshoring lever to the utmost – offshoring in Q4 reached a record high of 60.2% of quarterly revenue.

**Deal wins robust:** LTI's net new TCV rose 21% YoY to US\$ 80mn and constitutes four large deals, with a robust pipeline. Three deals are with Fortune 500 clients and one with a new account. Two wins were from BFS, with one each in the CPG and government healthcare verticals. Per management, the large-deal pipeline stands at ~US\$ 2bn and LTI is seeing broad-based demand across verticals and service lines.

**FY23 outlook strong:** LTI does not anticipate any slowdown in the demand environment but acknowledged uncertainty in terms of rising input costs and the volatile geopolitical climate. However, management expects to deliver leader quadrant growth in FY23 and PAT margin in the range of 14-15%.

**Other takeaways:** The board announced a dividend of Rs 30/sh (FY22 dividend at Rs 55/sh). DSO stood at 99 days in Q4 vs. 100 in Q3.

**Maintain BUY:** Factoring in the Q4 result, we cut FY23/FY24 EPS by 4%/2%. On rolling valuations over to Jun'24, our TP reduces to Rs 8,140 (from Rs 8,490) based on an unchanged 48.5x P/E. Maintain BUY on a robust demand environment.

**Key changes**

Target	Rating
▼	◀ ▶

Ticker/Price	LTI IN/Rs 5,472
Market cap	US\$ 12.6bn
Free float	25%
3M ADV	US\$ 29.3mn
52wk high/low	Rs 7,589/Rs 3,525
Promoter/FPI/DII	75%/8%/10%


Source: NSE | Price as of 19 Apr 2022

**Key financials**

Y/E 31 Mar	FY21A	FY22A	FY23E
Total revenue (Rs mn)	123,698	156,687	185,784
EBITDA (Rs mn)	27,253	30,585	38,783
Adj. net profit (Rs mn)	19,383	22,986	27,454
Adj. EPS (Rs)	110.5	131.0	156.4
Consensus EPS (Rs)	110.5	125.4	145.8
Adj. ROAE (%)	30.5	28.5	28.6
Adj. P/E (x)	49.5	41.8	35.0
EV/EBITDA (x)	35.2	31.4	24.8
Adj. EPS growth (%)	27.8	18.6	19.4

Source: Company, Bloomberg, BOBCAPS Research

**Stock performance**



Source: NSE



## Disclaimer

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Rating distribution

As of 31 March 2022, out of 116 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 65 have BUY ratings, 31 have HOLD ratings, 5 are rated ADD\*, 1 is rated REDUCE\* and 14 are rated SELL. One company rated ADD has been an investment banking client in the last 12 months. (\*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed

in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.